LA
NRXP icon

Linden Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Linden Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-36,435
Closed -$4.23M – 652
2021
Q2 		$4.23M Buy
+36,435
New +$9.62M 0.02% 364

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Linden Advisors's NRXP Position: Q3 2021 in Review

Linden Advisors sold out of NRX Pharmaceuticals (NRXP) in Q3 2021, closing a stake of 36,435 shares — an estimated $4.23M sold.

Linden Advisors first reported a position in NRXP in Q2 2021 and held it in 1 quarter. The position peaked at $4.23M in Q2 2021. 23 funds tracked by Wall St. Rank hold NRXP as of Q3 2021.

  • Linden Advisors reported no remaining NRX Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Linden Advisors sold 36,435 NRX Pharmaceuticals shares in Q3 2021, an estimated $4.23M.
  • Linden Advisors first reported a position in NRX Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Linden Advisors's NRX Pharmaceuticals position peaked at $4.23M in Q2 2021.
  • 23 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2021.

Based on Linden Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.